Wellgistics Health Inc. Stock Price, News & Analysis

Wellgistics Health (NASDAQ:WGRX) began commercial launch of diabetes drug Brenzavvy to its 6,500+ independent pharmacy network on December 8, 2025. The launch targets ~33 million U.S. adults with type II diabetes and positions Brenzavvy against entrenched SGLT-2 inhibitors that reached $16.8 billion in sales in 2024, with a projected market of $28.9 billion by 2033. Wellgistics is rolling out its EinsteinRx™ AI at point-of-sale to alert pharmacists to guideline-recommended candidates (reported 11.9% current uptake) and to support pharmacist-led provider education and patient access via lower out-of-pocket cash pricing.

Wellgistics Health (NASDAQ:WGRX) announced a 1-for-1 distribution of the Dream Bowl 2026 Meme Coin to shareholders of record on December 19, 2025. The ex-dividend date is December 20, 2025. Shareholders will receive one meme coin for each share owned on the record date, with a distribution to occur on or after December 20, 2025 and within 30 days following the record date in coordination with DataVault AI (NASDAQ:DVLT).

The digital collectible embeds ticketing and event details and will be airdropped to shareholder wallets after holders provide wallet information via notices coordinated with the transfer agent. The Dream Bowl event is scheduled for January 11, 2026 at AT&T Stadium in Dallas, Texas.

Wellgistics Health (NASDAQ:WGRX) announced sponsorship of Dream Bowl 2026 and participation in the DataVault AI (NASDAQ:DVLT) Shareholder Distribution Plan. The company plans to distribute a Dream Bowl 2026 Meme Coin to Wellgistics shareholders with a record date and distribution date expected to be set in December 2025, and distribution anticipated in January 2026.

The token is described as a digital collectible carrying ticketing and event metadata; handcrafted coins will be airdropped to DataVault wallets for eligible shareholders. Wellgistics will provide instructions for registering and configuring wallets and for trading the meme coins after the distribution date is set.

Wellgistics Health (NASDAQ:WGRX) reported third quarter 2025 results and provided a business update on November 20, 2025. The company recorded a net operating loss of $33.878M in Q3 2025 versus $1.867M in Q3 2024, and net loss per share $0.46 on 74.379M weighted average shares (vs $0.04 on 48.403M).

Management highlighted the completion of the EinsteinRx AI pharmacy hub software and a sales focus on launching Brenzavvy for the Type 2 diabetes market. The company expects a GLP-1 side-effect product to launch in Q1 2026 and is in advanced discussions to license blockchain smart-contract IP with DataVault AI in Q4 2025 or Q1 2026.

Wellgistics Health (NASDAQ:WGRX) will report third quarter 2025 financial results and provide a business update on the morning of Thursday, November 20, 2025.

The results will cover the period ended September 30, 2025. The company operates in health information technology for prescription drug distribution from manufacturer to patient through licensed pharmacies.

Wellgistics Health (NASDAQ:WGRX) expanded distribution with Tollo Health to offer a branded GLP-1 companion muscle-loss medical food to its 6,500+ independent pharmacy network and physicians, positioned as an adjunct to GLP-1 therapies to mitigate muscle loss during and after treatment.

The company also added 3CL protease inhibitor Tollovid® to its galectin 1 & 3 inhibitor medical food Galectovid™, creating a natural antiviral combination aimed at Long COVID. The release cites a GLP-1 muscle-loss market of $53B today and an expected $156B by 2030.

Wellgistics Health (NASDAQ:WGRX) launched EinsteinRx, a prescription management hub to integrate physical and technology healthcare infrastructure across physicians, an in-house pharmacy and a >6,500 independent pharmacy network.

The platform links manufacturing, insurance, patient data, nutritional guidance and fulfillment, and the company said it expects to begin onboarding new payer clients in Q4 2025. Wellgistics positions EinsteinRx to support its PharmacyChain™ smart contracts and access the $634 billion U.S. prescription drug market.

Wellgistics Health (NASDAQ: WGRX) entered a non-binding letter of intent to acquire Kare Rx Hub, an AI-based digital pharmacy hub owned by Dr. Kiran Patel, in an all-stock deal expected to close by January 31, 2026. KareRx contributes a plug-and-play telemedicine pharmacy-support vertical, over 500 physician-provider relationships, >200 independent pharmacy relationships, and three manufacturer relationships. Management cites integration with a patent-protected blockchain platform via an emerging relationship with DataVault AI. The acquisition targets the expanding telemedicine remote dispensing market, projected to grow from $6.7B in 2025 to $13.57B by 2032 according to Fortune Business Insights.

DataVault AI (NASDAQ: DVLT) and Wellgistics Health (NASDAQ: WGRX) entered a SAAS smart‑contract services agreement to develop PharmacyChain™, a manufacturer‑to‑patient blockchain tracking and dispensing platform targeting the $639 billion prescription drug market. The companies expect to finalize a profit‑sharing license in Q4 2025 and begin beta testing in H1 2026. DataVault AI cites issued U.S. patents dated April 16, 2024; June 25, 2024; and September 24, 2024 that it says cover blockchain, token‑driven data monetization and related IP. Management cites early inbound interest from manufacturers, pharmacists and insurers and describes plans for opt‑in biometric/diagnostic data and utility token monetization to enable new revenue streams.